Trials / Conditions / Bipolar 1 Disorder

Bipolar 1 Disorder

18 registered clinical trials studyying Bipolar 1 Disorder — 8 currently recruiting.

Status	Trial	Sponsor	Phase
Not Yet Recruiting	Socio-cognitive and Biological Responses to Maltreatment NCT07101107	Medical University Innsbruck	—
Enrolling By Invitation	Retrospective Observational Study of Blood-based Biomarkers in the Diagnosis and Monitoring of Patients With a NCT07314190	Fundació Institut de Recerca de l'Hospital de la Santa Creu i Sant Pau	—
Enrolling By Invitation	Prospective Observational Study of the Relationship Between Sociodemographic Factors, Blood-based Biomarkers a NCT07239843	Fundació Institut de Recerca de l'Hospital de la Santa Creu i Sant Pau	—
Recruiting	Pharmacokinetics, Safety, Tolerability and Efficacy of a Subcutaneous Long-Acting Injection of Cariprazine (Ca NCT07185815	Mapi Pharma Ltd.	Phase 1 / Phase 2
Recruiting	Study Evaluating the Efficacy and Safety of RAP-219 in Adult Participants With Bipolar I Disorder NCT07046494	Rapport Therapeutics Inc.	Phase 2
Recruiting	Feasibility and Preliminary Results of the Efficacy of Blue-Blocking Glasses on Manic Symptoms in Bipolar Diso NCT07194278	Centre Hospitalier St Anne	N/A
Active Not Recruiting	Efficacy and Safety of Endoxifen in Bipolar I Disorder Patients NCT06608641	Jina Pharmaceuticals Inc.	Phase 3
Recruiting	Biomarkers/Biotypes, Course of Early Psychosis and Specialty Services NCT06740383	Beth Israel Deaconess Medical Center	—
Completed	Efficacy of the Mobile Application for Prediction and Prevention of Mood Episode Recurrence Based on Machine L NCT05400785	Hucircadian	N/A
Recruiting	CLOZAPINE Response in Biotype-1 NCT04580134	University of Texas Southwestern Medical Center	Phase 4
Suspended	A Non-Interventional Pilot Study to Explore the Role of Gut Flora in Disease NCT04031469	ProgenaBiome	—
Terminated	A Trial to Measure the Difference in All-cause Hospitalizations for Participants Who Are Using Abilify MyCite NCT03643159	Otsuka Pharmaceutical Development & Commercialization, Inc.	Phase 4
Completed	Abilify Maintena PMS in Schizophrenia Patients or Bipolar 1 Disorder NCT03386851	Korea Otsuka Pharmaceutical Co., Ltd.	—
Withdrawn	Adherence to Treatment, Safety and Tolerability Study of the Medical Information Device #1 (MIND1) in Subjects NCT01981811	Otsuka Pharmaceutical Development & Commercialization, Inc.	Phase 2
Completed	Open-Label Observational Pilot Study to Evaluate the Pharmacokinetics of Aripiprazole in Subjects With Bipolar NCT02050854	Otsuka Pharmaceutical Development & Commercialization, Inc.	—
Terminated	Safety and Efficacy Study of ELND005 as an Adjunctive Maintenance Treatment in Bipolar I Disorder NCT01674010	OPKO Health, Inc.	Phase 2
Completed	Fixed-dose Safety and Efficacy Study of Asenapine for the Treatment of Acute Manic or Mixed Episode in Bipolar NCT00764478	Organon and Co	Phase 3
Completed	Efficacy and Safety of Asenapine in the Prevention of Recurrence of Mood Episodes in Participants With Bipolar NCT01396291	Forest Laboratories	Phase 3